Pfizer, Moderna say vaccine effectiveness wanes over time
The US companies Pfizer and Moderna, which produce COVID-19 vaccines using messenger RNA (mRNA) technology, announced research findings Wednesday showing that their vaccines’ effectiveness gradually wanes over time, Reuters and other news sources reported.
In data submitted ahead of discussions for US Food and Drug Administration (FDA) approval of a vaccine booster shot that day, Pfizer shared clinic trial findings indicating that the effectiveness of its vaccine began to gradually decline six to eight months after the administration of the second dose.
According to the company’s findings, the effectiveness dropped at a rate of 6% every two months. While the vaccine’s effectiveness was calculated at 96.2% the week after administration of the second dose, it fell to 83.7% four months later, Pfizer said.
Moderna shared its own findings at an investor briefing the same day.
In a study of 14,000 people given the vaccine since July 2020, effectiveness was found to decline over time, the company said.
Of the people who received the vaccine last year, 162 were found to have become infected with COVID-19, while 88 confirmed cases were counted among those who had received the vaccine since then, Reuters reported.
Only 19 of those studied developed severe symptoms, it added, explaining that the matter of whether patients experience severe symptoms is particularly important in judging a vaccine’s protection capabilities.
But the FDA indicated that the research findings were “not conclusive on whether the vaccine’s ability to stop symptomatic infection declined,” the Financial Times reported.
In explanatory materials released the same day, the FDA said that in general, the COVID-19 vaccines currently approved in the US showed adequate protection capabilities against severe cases and death.
An FDA advisory committee is set to conduct a review Friday on the vaccine makers’ request to approve booster shots.
Experts are also divided on the question of whether booster shots need to be administered to people who have received their recommended doses.
In a contribution to the British journal The Lancet on Monday, eminent researchers including FDA vaccine advisors Philip Krause and Marion Gruber and World Health Organization Chief Scientist Soumya Swaminathan said booster shots were not currently necessary for the general population.
Among the researchers credited on the contribution were major vaccine researchers in the US, the UK, France, India and South Africa.
By Shin Gi-sub, senior staff writer
Please direct questions or comments to [email@example.com]
Copyright© 한겨레. 무단전재 및 재배포 금지.
- 국회 앞 ‘초라한 분향소’ 찾은 자영업자 “왜 그런 선택 했는지 잘 알아”
- 남은 시간 얼마 없다…‘고발 사주’ 수사, 닷새 연휴에도 속도 낸다
- 조성은 “당에 고발장 존재 알렸지만, 문건은 안줬다”
- ‘KTX 잡지’ 제작 업체 부도에…프리랜서 70여명, 6억 넘는 급여 떼여
- 중국 손실 메우려…소프트뱅크, 쿠팡 주식 2조원어치 매각
- 추석 지나면 어쩌려고? 벌써 1년치 80% 채운 수도권매립지
- 미국 ‘빅테크 M&A’ 브레이크 걸었다…국내도 ‘문어발’ 잡을까
- “내, 내가 확진?”…양성 1명에게 보낸다는 검사 결과 265명에게 통보
- ‘봉황’이라 불러다오…몸보다 1.5배 긴 꼬리, 새 화석 발견
- 가혹행위 신고한 해군을 ‘관심병사’로 보고한 강감찬함 함장